Skip to main content
MedPathMedPath Home
Clinical Trials/EUCTR2007-003077-44-IT
EUCTR2007-003077-44-IT
Active, not recruiting
Not Applicable

EffectS of PiogLitazone on ENDOthelial progenitoR cells in type 2 diabetic patients with vascular complications - The SPLENDOR Study - SPLENDOR

TAKEDA0 sitesJuly 3, 2008
Share to TwitterShare to FacebookShare to LinkedInShare to Reddit
ConditionsType 2 diabetesMedDRA version: 9.1Level: HLTClassification code 10012654Term: Diabetic complications cardiovascular
DrugsACTOSDAONIL

Overview

Phase
Not Applicable
Intervention
Not specified
Conditions
Type 2 diabetes
Sponsor
TAKEDA
Status
Active, not recruiting
Last Updated
14 years ago
OverviewInvestigatorsEligibility CriteriaOutcomesSimilar Trials

Overview

Brief Summary

No summary available.

Registry
who.int
Start Date
July 3, 2008
End Date
TBD
Last Updated
14 years ago
Study Type
Interventional clinical trial of medicinal product
Sex
All

Investigators

Sponsor
TAKEDA

Eligibility Criteria

Inclusion Criteria

  • •HbA1c\>7,5% and \<10%; age at onset of type 2 diabetes \>35 years; metfomine monotherapy up to the maximum tolerated daily dose; one or more cardiovascular comorbidity.
  • •Are the trial subjects under 18? no
  • •Number of subjects for this age range:
  • •F.1\.2 Adults (18\-64 years) yes
  • •F.1\.2\.1 Number of subjects for this age range
  • •F.1\.3 Elderly (\>\=65 years) yes
  • •F.1\.3\.1 Number of subjects for this age range

Exclusion Criteria

  • •insulin therapy; severe obesity; evidence of systemic deseases; cardiovascular deseases as unstable angina, myocardial infarction, bypass or PTCA within 3 months of study entry, heart failure.

Outcomes

Primary Outcomes

Not specified

Similar Trials

Completed
Not Applicable
Improvement effects of pioglitazone on endothelial function after sirolimus-eluting stent (Cypher stent) implantation: a randomized, open rabelled, prospective study.coronary artery disease
JPRN-UMIN000000899Chiba University Graduate School of Medicine50
Completed
Not Applicable
Effect of alogliptin/pioglitazone on endothelial function and Visceral fat of Type 2DiabetesType2 diabetes
JPRN-UMIN000023463Dokkyo medical university hospital30
Completed
Phase 4
Efficacy and Safety of Pioglitazone in Treating Subjects With Vascular Complications Associated With Type 2 Diabetes Mellitus.Diabetes Mellitus
NCT00770835Takeda39
Withdrawn
Phase 2
Endometriosis: ImmunomodulationEndometriosis
NCT01184144University of Wisconsin, Madison
Active, not recruiting
Phase 1
The effect of Pioglitazone on vascular and ventricular function in people with type 2 diabetes PICCOLA - PICCOLA
EUCTR2007-001222-27-GBImperial College London24